← Leaderboards
Lin Ji
University Of Tx Md Anderson Can Ctr
$1,518,176
Attributed
$2,668,266
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $519.3K · FY2007–16$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$2,668,266 · 2
By mechanism
R01$2,668,266 · 2
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Michael J Galko$9,739,468
- Jie Lin$696,384
- Ivan P Gorlov$3,179,655
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsProteinsMolecularMediatingMouse ModelNovel TherapeuticsDesignChemotherapyInheritedMalignant NeoplasmsBaseCessation Of LifeNanoparticleNeoplastic CellApoptosisCellsCancer EtiologyCancer CenterGene ExpressionGenesInnovationMalignant Neoplasm Of LungCancer CellResponse
Grant awards (7)
Epigenetic miRNA, SNP Signatures, and their Functions in Lung Cancer Outcomes$494,829
R01 · FY2016 · CA
Epigenetic miRNA, SNP Signatures, and their Functions in Lung Cancer Outcomes$519,312
R01 · FY2015 · CA
Epigenetic miRNA, SNP Signatures, and their Functions in Lung Cancer Outcomes$519,312
R01 · FY2014 · CA
Tumor and PTK-Targeted Therapy by FUS1 and PTK inhibitor$292,600
R01 · FY2010 · CA · contact PI
Tumor and PTK-Targeted Therapy by FUS1 and PTK inhibitor$292,600
R01 · FY2009 · CA · contact PI
Tumor and PTK-Targeted Therapy by FUS1 and PTK inhibitor$292,600
R01 · FY2008 · CA · contact PI
Tumor and PTK-Targeted Therapy by FUS1 and PTK inhibitor$257,013
R01 · FY2007 · CA · contact PI